Are there any restrictions on humira use in my plan?

Check Your Insurance Plan's Drug Formulary

Humira (adalimumab) often faces restrictions on many U.S. health plans due to its high cost and availability of cheaper biosimilars like Amjevita or Cyltezo. Log into your insurer's portal (e.g., via UnitedHealthcare, Blue Cross, or CVS Caremark) and search their formulary or preferred drug list—Humira is typically Tier 3 or 4 (non-preferred, higher copay) or requires prior authorization (PA).[1]

Common Restrictions on Humira

• Prior Authorization (PA): Most plans mandate PA to confirm medical necessity, like failed trials of methotrexate or other DMARDs for rheumatoid arthritis, psoriasis, or Crohn's disease.
  
• Step Therapy: You may need to try a lower-cost alternative (e.g., a biosimilar or generic) first.
  
• Quantity Limits: Caps on syringes/pens per fill, often 2-4 weeks' supply.
  
• Tier and Copay: Non-preferred status means 30-50% coinsurance; biosimilars are usually Tier 1 or 2 with $10-50 copays.[2]
  
  Plans updated formularies post-2023 Humira patent cliffs, favoring biosimilars—check yours for specifics like Express Scripts or OptumRx.
  
  

How to Verify for Your Plan

Call your insurer's member services (number on your card) or use tools like:
- GoodRx or SingleCare for copay estimates by ZIP code and plan.
- Medicare.gov's Plan Finder if on Part D.
Provide your plan ID; they confirm PA needs or appeals.

Biosimilar Switch Requirements

Some plans (e.g., CVS, Cigna) auto-switch to interchangeable biosimilars unless you opt out via PA. FDA-approved options match Humira's efficacy/safety for approved uses.[3]

Cost if Restricted

Without coverage, Humira lists at $6,000+ monthly; patient assistance via AbbVie (myAbbVieAssist) or NeedyMeds can help uninsured/low-income patients.

[1]: DrugPatentWatch.com - Humira Patents and Biosimilars
[2]: FDA Biosimilars Page
[3]: CMS Medicare Formulary Lookup